Prepared Remarks:

Operator

Hello, and welcome to the Q3 fiscal year 2022 ResMed call. My name is Kevin, and I'll be your operator for today's call. [Operator instructions] Please note that this conference is being recorded. I will now turn the call over to Amy Wakeham, vice president of investor relations and corporate communications.

Amy, you may begin.

Amy Wakeham -- Vice President of Investor Relations and Corporate Communications

Great. Thank you, Kevin. Hi, everyone, and welcome to ResMed's third quarter fiscal year 2022 earnings conference call. We appreciate you joining us.

This call is being webcast live and the replay will be available on the Investor Relations section of our corporate website later today, along with a copy of our earnings press release and presentation, which are both available now. With me on the call today are ResMed's chief executive officer, Mick Farrell; and chief financial officer, Brett Sandercock. During the Q&A portion of our call, Mick and Brett will be joined by Rob Douglas, president and chief operating officer; Jim Hollingshead, president, sleep and respiratory care; and David Pendarvis, our chief administrative officer and global general counsel. During today's call, we will discuss several non-GAAP measures.

For a reconciliation of these non-GAAP measures, please review the supporting schedules in today's earnings release or the appendix of the earnings presentation. As a reminder, our discussion today will include forward-looking statements, including, but not limited to, expectations about our future operating and financial performance. We believe these statements are based on reasonable assumptions, However, our actual results may differ. You are encouraged to review our SEC filings for a discussion of the risk factors that could cause our actual results to differ materially from any forward-looking statements that are made today.

I'd like to now turn the conference call over to Mick.

Mick Farrell -- Chief Executive Officer

Thanks, Amy, and thank you to all of our shareholders for joining us today as we review results for the third quarter of our fiscal year 2022 ended March 31st. Our third quarter results reflect strong performance across our business with double-digit revenue growth in our sleep and respiratory care business and high single-digit growth in our Software-as-a-Service segment. Our growth is the direct result of our global team's ability to pivot and drive for results even as we continue to manage through several external challenges that are impacting our business, including one, ongoing supply chain disruptions; two, COVID restrictions in parts of the world; three, recovering post-COVID peak patient flows; and four, unprecedented demand from a competitor recall, which will keep them out of the market at least through the end of the calendar year. The global supply chain environment remains very challenging across multiple industries.